Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Corvus Pharma Q2 EPS $(0.10) Beats $(0.13) Estimate

Author: Benzinga Newsdesk | August 07, 2025 03:01pm
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 25.37 percent. This is a 42.86 percent decrease over losses of $(0.07) per share from the same period last year.

Posted In: CRVS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist